ERBB2 and neoplasm: Review of TN tumor subgroups in adjuvant therapy studies, in the case of CALGB 9344 (patients with positive axillary nodes to compare the addition of pacli-taxel to different anthracycline doses), shows significant benefits (P = 0.002) for this combination, although the benefits were independent of HER2 status [28].